GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Propanc Biopharma Inc (OTCPK:PPCB) » Definitions » Shiller PE Ratio

PPCB (Propanc Biopharma) Shiller PE Ratio : (As of Apr. 27, 2025)


View and export this data going back to 2012. Start your Free Trial

What is Propanc Biopharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Propanc Biopharma Shiller PE Ratio Historical Data

The historical data trend for Propanc Biopharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Propanc Biopharma Shiller PE Ratio Chart

Propanc Biopharma Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Propanc Biopharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Propanc Biopharma's Shiller PE Ratio

For the Biotechnology subindustry, Propanc Biopharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Propanc Biopharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Propanc Biopharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Propanc Biopharma's Shiller PE Ratio falls into.


;
;

Propanc Biopharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Propanc Biopharma's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Propanc Biopharma's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-32.22/129.4637*129.4637
=-32.220

Current CPI (Dec. 2024) = 129.4637.

Propanc Biopharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 0.000 99.187 0.000
201506 0.000 99.838 0.000
201509 0.000 100.302 0.000
201512 0.000 100.673 0.000
201603 0.000 100.488 0.000
201606 0.000 100.859 0.000
201609 0.000 101.602 0.000
201612 0.000 102.159 0.000
201703 0.000 102.624 0.000
201706 0.000 102.809 0.000
201709 0.000 103.460 0.000
201712 0.000 104.110 0.000
201803 0.000 104.574 0.000
201806 0.000 104.945 0.000
201809 0.000 105.410 0.000
201812 0.000 105.967 0.000
201903 0.000 105.967 0.000
201906 0.000 106.617 0.000
201909 0.000 107.174 0.000
201912 0.000 107.917 0.000
202003 0.000 108.289 0.000
202006 0.000 106.246 0.000
202009 0.000 107.917 0.000
202012 0.000 108.846 0.000
202103 0.000 109.496 0.000
202106 0.000 110.332 0.000
202109 0.000 111.168 0.000
202112 -893,375.000 112.654 -1,026,682.038
202203 -700,076.000 115.069 -787,656.302
202206 -386,491.333 117.112 -427,255.330
202209 -91,502.727 119.248 -99,341.804
202212 -25,237.000 121.477 -26,896.313
202303 -18,832.767 123.148 -19,798.550
202306 -8,057.600 124.170 -8,401.117
202309 -1,997.737 125.656 -2,058.275
202312 -1,028.188 126.399 -1,053.119
202403 -296.772 127.606 -301.092
202406 -44.935 128.906 -45.129
202409 -287.823 129.185 -288.444
202412 -32.220 129.464 -32.220

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Propanc Biopharma  (OTCPK:PPCB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Propanc Biopharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Propanc Biopharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Propanc Biopharma Business Description

Traded in Other Exchanges
N/A
Address
302, 6 Butler Street, Cambwerwell, VIC, AUS, 3124
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
Executives
Josef Zelinger director 59 SEYMOUR ROAD, ELSTERNWICK C3 3185
Carlo M Campiciano officer: CFO & Secretary C/O. PROPANC BIOPHARMA,INC., 302, 6 BUTLER STREET, CAMBERWELL C3 3124
Julian Norman Kenyon director BEECHWOOD, EMBLEY LANE, EAST WELLOW, ROMSEY HAMPSHIRE X0 SO516DN
James Andrew Nathanielsz director, officer: CEO, CFO, Secretary, Treasurer 1/76 SUMMERHILL ROAD, GLEN IRIS, VICTORIA C3 3146